Holen Sie sich die Stockscreener-App
103.76
0.86%
0.88
Handel nachbörslich:
104.19
0.43
+0.41%
Schlusskurs vom Vortag:
$102.88
Offen:
$102.78
24-Stunden-Volumen:
612.20K
Relative Volume:
0.54
Marktkapitalisierung:
$26.06B
Einnahmen:
$3.26B
Nettoeinkommen (Verlust:
$-1.45B
KGV:
-17.67
EPS:
-5.871
Netto-Cashflow:
$1.18B
1W Leistung:
+1.65%
1M Leistung:
+13.59%
6M Leistung:
-0.04%
1J Leistung:
+0.25%
1-Tages-Spanne:
$102.33
$104.82
1-Wochen-Bereich:
$100.30
$105.46
52-Wochen-Spanne:
$79.52
$124.00
Biontech Se Adr Stock (BNTX) Company Profile
Compare BNTX vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BNTX
Biontech Se Adr
|
103.76 | 27.86B | 3.26B | -1.45B | 1.18B | -5.871 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Biontech Se Adr Stock (BNTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-02 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2026-01-16 | Hochstufung | Goldman | Neutral → Buy |
| 2025-06-05 | Bestätigt | H.C. Wainwright | Buy |
| 2025-05-29 | Eingeleitet | Goldman | Neutral |
| 2025-03-13 | Eingeleitet | Citigroup | Buy |
| 2025-01-10 | Eingeleitet | Truist | Buy |
| 2024-12-11 | Eingeleitet | Wells Fargo | Overweight |
| 2024-12-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2024-11-19 | Eingeleitet | Berenberg | Buy |
| 2024-11-19 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-11-08 | Hochstufung | Goldman | Neutral → Buy |
| 2024-09-24 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-09-17 | Hochstufung | Jefferies | Hold → Buy |
| 2024-09-16 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2024-08-07 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-08-02 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-05-14 | Eingeleitet | Evercore ISI | In-line |
| 2024-02-23 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-01-05 | Eingeleitet | Oppenheimer | Perform |
| 2023-12-01 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-10-16 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-05-17 | Hochstufung | Redburn | Neutral → Buy |
| 2022-12-15 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-08-17 | Eingeleitet | Cowen | Market Perform |
| 2022-07-13 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-07-06 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-02-01 | Hochstufung | Redburn | Sell → Neutral |
| 2021-12-16 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-11-10 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2021-10-22 | Eingeleitet | Deutsche Bank | Hold |
| 2021-10-07 | Eingeleitet | Jefferies | Hold |
| 2021-08-11 | Hochstufung | Bryan Garnier | Neutral → Buy |
| 2021-07-19 | Fortgesetzt | Wolfe Research | Outperform |
| 2021-06-16 | Herabstufung | Redburn | Neutral → Sell |
| 2021-05-18 | Eingeleitet | Goldman | Neutral |
| 2021-05-11 | Herabstufung | Bryan Garnier | Buy → Neutral |
| 2020-12-01 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-08-03 | Fortgesetzt | Berenberg | Buy |
| 2020-07-21 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-06-30 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-05-19 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-04-28 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2020-03-18 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-03-09 | Eingeleitet | H.C. Wainwright | Neutral |
| 2020-01-24 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-01-22 | Herabstufung | UBS | Buy → Neutral |
| 2019-11-05 | Eingeleitet | Wolfe Research | Outperform |
| 2019-11-04 | Eingeleitet | Berenberg | Buy |
| 2019-11-04 | Eingeleitet | BofA/Merrill | Buy |
| 2019-11-04 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-11-04 | Eingeleitet | JP Morgan | Overweight |
| 2019-11-04 | Eingeleitet | SVB Leerink | Outperform |
| 2019-11-04 | Eingeleitet | UBS | Buy |
Alle ansehen
Biontech Se Adr Aktie (BNTX) Neueste Nachrichten
Market Wrap: Stocks Fall as Industrials and Utilities Decline - Morningstar
BioNTech’s New HIV RNA Vaccine Trial: What Investors Should Watch Now - TipRanks
BioNTech jumps $5.1 billion in premarket; analyst target now just 8% higher - TechStock²
Merck Raises the Stakes for Pfizer's Cancer Vaccine AmbitionsModerna (NASDAQ:MRNA), Merck & Co (NYSE:M - Benzinga
Is Cancer the Next Breakthrough for Moderna After COVID-19? - TradingView
Moderna ascends more than 175% from cancer vaccine breakthrough - Mugglehead Investment Magazine
BioNTech SEADR (BNTX) News, Articles, Events & Latest Updates - Stocktwits
BioNTech SE Stock Jumps As Traders Bet On Post-COVID Pivot - StocksToTrade
European ADRs Rose In US Trading, Led By BioNTech - Finimize
Let's uncover which stocks are experiencing notable gaps during today's session. - ChartMill
Estee Lauder, Moderna, Merck And Other Big Stocks Moving Higher On Wednesday - Benzinga
BioNTech Up Over 21%, On Track for Largest Percent Increase Since May 2020 -- Data Talk - Moomoo
BNTX Stock Quote Price and Forecast - CNN
U.S. Listings For German Scale-ups | Part 2 - orrick.com
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
BIONTECH SE BIONTECH SE ADR (0A3M.L) Q1 FY2026 earnings call transcript - Yahoo Finance
BioNTech Just Named a New CEO. Here's What Guido Oelkers' Appointment Means for the Stock. - The Motley Fool
BioNTech SE (BNTX) stock price, news, quote and history - Yahoo Finance Australia
BioNTech (BNTX) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
Pfizer Rises Almost 7% Post Q2 Results: How to Play the Stock - TradingView
Bank of America Corp DE Raises Stake in BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech's Double Whammy: A CEO Transition Lands in the Middle of a Guidance Cut () - aktiencheck.de
Assenagon Asset Management S.A. Makes New $39.38 Million Investment in BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech's Second Quarter Puts a Founder's Exit and a Shrinking COVID Franchise in Sharp Relief - aktiencheck.de
Bank of New York Mellon Corp Trims Stock Position in BioNTech SE Sponsored ADR $BNTX - MarketBeat
Pfizer and BioNTech Advance Next‑Season Pediatric COVID‑19 Booster Strategy With New Phase 3 Update - TipRanks
Pfizer and BioNTech Advance Variant-Adapted COVID-19 Booster in New Phase 4 Study - tipranks.com
BioNTech SE Sponsored ADR Revenue Breakdown – BSESOF:22UA - TradingView
Caution with BioNTech! Novo Nordisk Accelerates! Buying Opportunity in Vidac Pharma Stock? - news.financial
Pfizer and BioNTech Lock In Next-Gen Pediatric COVID Booster Edge - TipRanks
BioNTech Earnings Call: COVID Slide, Oncology Push - tipranks.com
BioNTech SE (BNTX) Stock Forecasts - Yahoo Finance
BioNTech's Promising Oncology Pipeline Is Now in Late-Stage Development - Morningstar
Earnings call transcript: BioNTech Q2 2026 revenue falls, shares slip premarket - Investing.com
BioNTech Q2 Earnings Call Highlights - Yahoo Finance
Weekly Recap: BioNTech CEO succession and Q2 2026 loss forecast - TradingView
Biontech Se Sponsored Adr (BNTXN) Q4 2022 Earnings ReportResults, Call & Slides - TipRanks
Enterprise value to revenue forward of BioNTech SE Sponsored ADR – BX:22UA - TradingView
Spontaneous reporting of adverse reactions... : Porto Biomedical Journal - Ovid
Weekly Recap: Q2 2026 results, investor call and Moderna IP response - TradingView
First Trust Advisors LP Acquires 451,124 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
Aristides Capital LLC Decreases Holdings in BioNTech SE Sponsored ADR $BNTX - MarketBeat
Biontech Se Sponsored Adr (BNTXN) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Biontech Se Sponsored Adr (BNTXN) Q1 2026 Earnings ReportResults, Call & Slides - TipRanks
Biontech Se Sponsored Adr (BNTXN) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Biontech Se Sponsored Adr (BNTXN) Q2 2025 Earnings ReportResults, Call & Slides - TipRanks
Biontech Se Sponsored Adr (BNTXN) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
Biontech Se Sponsored Adr (BNTXN) Q2 2024 Earnings ReportResults, Call & Slides - TipRanks
Biontech Se Sponsored Adr (BNTXN) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Biontech Se Sponsored Adr (0A3M) Q4 2022 Earnings ReportResults, Call & Slides - TipRanks
Biontech Se Sponsored Adr (BNTXN) Earnings Dates, Call Summary & Reports - TipRanks
Finanzdaten der Biontech Se Adr-Aktie (BNTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Biontech Se Adr-Aktie (BNTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Poetting Sierk | Chief Operating Officer |
Apr 22 '26 |
Sale |
110.56 |
50,000 |
5,527,960 |
399,387 |
0.29%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):